In vivo biological fate of poly(vinylalcohol) microbubbles in mice. Issue 9 (September 2018)

• Record Type: Journal Article
• Authors: Cerroni, Barbara; Cicconi, Rosella; Oddo, Letizia; Scimeca, Manuel; Bonfiglio, Rita; Bernardini, Roberta; Palmieri, Graziana; Domenici, Fabio; Bonanno, Elena; Mattei, Maurizio; Paradossi, Gaio
• Is Part Of: Heliyon. Volume 4:Issue 9(2018)
• Publication Date: 2018-09
• Subjects: Biochemistry -- Bioengineering -- Cell biology -- Medical imaging; Research -- Periodicals; Medical sciences -- Periodicals; Natural history -- Periodicals; Social sciences -- Periodicals; Earth sciences -- Periodicals; Physical sciences -- Periodicals; 507.2
• DOI: 10.1016/j.heliyon.2018.e00770
• Languages: English
• ISSNs: 2405-8440

Abstract

Abstract: Microbubbles (MBs) are used in clinical practice as vascular ultrasound contrast agents, and are gaining popularity as a platform supporting multimodal imaging and targeted therapy, facilitating drug delivery under ultrasound exposure. Here, we report on the in vivo biological impact of newly discovered MBs with promising features as a multimodal theranostic device. The shell of the air-filled MBs is made of the poly(vinyl alcohol) (PVA), a well-established, FDA-approved polymer. Nevertheless, as size, shape and dispersity can significantly impact the biological response of particulate systems, studying their fate after administration is crucial. The safety and the biodistribution of PVA MBs were analysed in vivo and ex vivo by coupling a near infrared (NIR) fluorophore on their shell: MBs accumulated mainly in liver and spleen at 24 hours post-injection with their clearance from the spleen 7 days post-dosing. A possible way of elimination was identified in macrophages ability to engulf MBs both in vitro and in vivo . One month post-dosing, transmission electron microscopy (TEM) highlighted the lack of relevant defects and the elimination of PVA MBs by Kupffer cells. This study is the first successful attempt to fill the lack of knowledge necessary to bring PVA MBs one step closer to their possible clinical use.